Skip to main content

Table 1 Baseline demographic and laboratory variables randomized in 2 arms

From: The effect of EMPAgliflozin on markers of inflammation in patients with concomitant type 2 diabetes mellitus and Coronary ARtery Disease: the EMPA-CARD randomized controlled trial

Parameters

Empagliflozin

(n = 47)

Placebo

(n = 48)

Mean Diff

P

95% CI

Demographic

 Age

62.08 (8.02)

63.60 (7.82)

-1.52

0.352

− 4.75; 1.71

 Gender

   

0.122

 

  Male

23 (48.9%)

16 (33.3%)

   

  Female

24 (51.1%)

32 (66.7%)

   

 Comorbidities (yes)

  HTN

44 (93.6%)

43 (89.6%)

 

0.714

 

  HLP

38 (80.9%)

34 (70.8%)

 

0.339

 

 Drug history (yes)

  Metformin

46 (97.9%)

46 (95.8%)

 

0.999

 

  Sulfonylurea

17 (36.2%)

13 (27.1%)

 

0.341

 

  DPP4-i

8 (17.0%)

4 (8.3%)

 

0.232

 

  Insulin

4 (8.5%)

3 (6.3%)

 

0.714

 

  BB

42 (89.4%)

44 (91.7%)

 

0.740

 

  ACEi/ARB

41 (87.2%)

43 (89.6%)

 

0.720

 

  CCB

17 (36.2%)

15 (31.3%)

 

0.612

 

  Diuretic

20 (42.6%)

20 (41.7%)

 

0.930

 

  Statins

46 (97.9%)

44 (91.7%)

 

0.362

 

Laboratory

 IL-6 (pg/mL)

4.91 (1.83)

5.19 (2.10)

-0.28

0.492

− 1.10; 0.53

 IL-1b (pg/mL)

37.06 (10.36)

34.05 (10.24)

3.00

0.171

− 1.32; 7.32

 Hs-CRP (mg/L)

10.07 (8.79)

9.85 (7.90)

0.22

0.901

− 3.29; 3.73

 SOD (U/mL)

12.58 (6.32)

11.22 (6.49)

1.36

0.316

− 1.32; 4.05

 CAT (mU/mL)

436.19 (148.58)

427.50 (101.81)

8.69

0.747

− 44.67; 62.06

 GSHr (muM)

3.09 (0.74)

3.26 (0.95)

-0.17

0.350

− 0.53; 0.19

 ROS

1087.25 (687.91)

1010.22 (669.83)

77.03

0.592

− 207.39; 361.46

 TAC (mmol/l)

645.38 (80.52)

666.49 (81.70)

-21.11

0.223

− 55.30; 13.08

 MDA (nmol/mL)

6.25 (0.83)

6.31 (1.08)

-0.06

0.752

− 0.47; 0.34

 PCG (nmol/mg)

0.11 (0.5)

0.12 (0.06)

-0.01

0.568

− 0.03; 0.02

 CD62-P Ag Exp

231.26 (37.96)

238.78 (32.93)

-7.53

0.322

− 22.55; 7.50

 FBS (mg/dL)

163.14 (40.84)

167.74 (48.64)

-4.60

0.629

− 23.48; 14.28

 HbA1c (%)

8.05 (0.97)

7.75 (0.94)

0.30

0.141

− 0.10; 0.70

 HOMA-IR

6.52 (3.17)

7.01 (3.48)

-0.49

0.514

− 1.99; 1.00

 Calcium (mg/dL)

9.73 (0.51)

9.53 (0.53)

0.21

0.078

− 0.02; 0.44

 Sodium (mEq/L)

139.38 (4.34)

138.45 (2.34)

0.93

0.239

− 0.63; 2.48

 Potassium (mmol/L)

4.31 (0.37)

4.33 (0.47)

0.87

-0.015

− 0.21; 0.18

 WBC count (× 109/L)

7.34 (1.93)

7.08 (1.44)

0.27

0.484

− 0.49; 1.03

 Hb (g/dL)

13.87 (1.49)

13.88 (1.57)

-0.00

0.991

− 0.68; 0.67

 Hematocrit (%)

41.32 (4.46)

40.76 (4.14)

0.56

0.560

− 1.35; 2.47

 Plt count (× 109/L)

240.38 (76.53)

220.21 (55.10)

20.17

0.181

− 9.59; 49.93

 BUN (mmol/L)

14.81 (3.95)

16.81 (7.31)

-2.00

0.121

− 4.55; 0.54

 Creatinine (mg/dL)

0.98 (0.19)

1.01 (0.23)

-0.04

0.413

− 0.13; 0.05

 AST (U/L)

16.95 (6.56)

20.28 (10.21)

-3.33

0.078

− 7.03; 0.38

 ALT (U/L)

21.26 (11.52)

23.02 (13.23)

-1.76

0.514

− 7.11; 3.59

 PTT (Sec)

32.60 (5.63)

30.86 (5.13)

1.73

0.153

− 0.66; 4.13

IPAQ

 Physical Activity (MET min/week)

968.63 (627.53)

871.37 (511.16)

97.26

0.450

− 157.99; 352.51

FFQ

 TEI (Kcal/day)

2166.72 (283.78)

2090.49 (337.12)

56.46

0.413

− 80.25; 193.17

 PHYs Intake (Kcal/day)

856.42 (203.88)

792.61 (218.19)

59.04

0.232

− 38.47; 156.55

 DPI

39.53 (7.61)

28.27 (9.93)

1.39

0.493

− 2.62; 5.39

 TPI (g/day)

90.32 (18.47)

84.00 (15.21)

4.80

0.215

− 2.84; 12.44

 TSI (g/day)

106.18 (21.34)

109.17 (16.36)

-3.76

0.398

− 12.57; 5.05

  1. Data are presented as mean (SD) or frequency (%)
  2. HTN Hypertension, HLP Hyperlipidemia, DPP4-i Inhibitors of dipeptidyl peptidase-4 inhibitor, BB Beta blocker, ACEi Angiotensin convertase enzyme inhibitor, ARB Angiotensin receptor blocker, CCB Calcium channel blocker, IL-6 Interleukin 6, IL-1B Interleukin 1-B, Hs-CRP High Sensitivity C-Reactive Protein, SOD Superoxide dismutase Enzyme Activity, CAT Catalase enzyme activity, GSHr Reduced glutathione, ROS Reactive oxygen species, TAC Total antioxidant Capacity, MDA Malondialdehyde, PCG Protein carbonyl groups, CD62-P Ag Exp CD62-P Ag Expression intensity, FBS Fasting blood sugar, HbA1c Glycated hemoglobin, HOMA-IR Homeostatic model assessment for insulin resistance, WBC White blood cell, Hb Hemoglobin, Plt Platelet, BUN Bound urea nitrogen, AST Aspartate aminotransferase, ALT Alanine aminotransferase, PTT Partial thromboplastin time, IPAQ International physical activity questionnaire, FFQ Food frequency questionnaire, TEI Total energy intake, PHYs intake Phytochemical intake, DPI Dietary phytochemical index, TPI Total protein intake, TSI Total sugar intake
  3. aValues are presented as Mean fluorescent intensity (MFI)
  4. bValues are presented as the level of PCG/ mg of protein